Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE CBL0137 decreased the viability of a panel of MLL-r leukemia cell lines (n = 12) and xenograft cells derived from patients with MLL-r acute lymphoblastic leukemia (ALL, n = 3) in vitro with submicromolar IC50s. 31325323 2020
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Although KMT2A rearrangement is the predominant genetic signature in infantile B-ALL, disease course is heterogenous, behaving more aggressively in younger infants. 30188223 2019
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE Multiple mice engrafted with MLL-r ALL remained disease free for more than 1 year after treatment. 31821784 2019
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE After referral to our clinic, tests of the morphology, immunology, cytogenetics, and molecular biology of his bone marrow led to a diagnosis of MLL-AF4 fusion positive B-cell ALL. 31192927 2019
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE ALL related to prior cytotoxic therapy (t-ALL) appears to be a distinct entity when compared to the de novo ALL, with characteristics including older age at the time of onset, female predominance and leukemia genetics enriched with KMT2A (MLL) gene rearrangement and chromosomes 5/7 abnormalities. 31235377 2019
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE Thus, defining mechanisms underlying MLL-r ALL maintenance is critical for developing effective therapy. 31395602 2019
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Pediatric acute myeloid leukemia (AML) with KMT2A rearrangement is detected in 15-20% of all pediatric AML patients and is associated with adverse outcomes even after allogeneic hematopoietic stem cell transplantation (HSCT). 31707119 2019
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Majority of the patients had<br /> pre-B-cell ALL (88.7%), WBC count <50, 000/μL at diagnosis (76.1%, median = 13.5/μL with a range of 0.51-553.0/<br /> μL) with involvement of central nervous system (CNS) disease in 8.5%patients.Different common chromosomal<br /> anomalies or abnormalities, including t(12, 21) translocation, MLL genre arrangements, trisomy (4, 10, 17)and others,<br /> were detected. 31759364 2019
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). 28819280 2018
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Such factors as younger age than 2 years old, MLL/AF4 fusion gene, poor response to prednisone, or no complete remission (CR) on TP3 were poor prognostic parameters in predicting the outcome in childhood ALL with MLL gene rearrangement treated with CCLG-ALL 2008 protocol. 30280786 2018
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE NRAS mutations were associated with a higher frequency of hyperdiploidy (P = 0.01) and lower frequency of ETV6-RUNX1 (P < 0.01), whereas KRAS mutations were associated with younger age (P < 0.01), a higher frequency of KMT2A rearranged (P < 0.01) but no significant difference if infants with ALL were excluded, and inferior event-free survival (66.6% vs. 80.5%, P = 0.04). 28853218 2018
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE Frozen/thawed CARCIK-CD19 remained fully functional both in vitro and in an established patient-derived xenograft (PDX) of MLL-ENL rearranged acute lymphoblastic leukemia (ALL). 29641322 2018
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE MLL+ALL has a unique gene profile distinguishable from other types of ALL and AML, and should be investigated separately in responses to biological active agents including chemokine inhibitors. 30453100 2018
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE This study aimed to determine the frequency of hypodiploidy, ETV6-RUNX1, BCR-ABL1, and MLL rearrangement within New Zealand's pediatric ALL population and to assess whether the frequency of these ALL prognostic markers varies according to ethnicity. 28598545 2017
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Deregulation of the epigenome is an important pathogenetic mechanism in acute lymphoblastic leukemia (ALL) with lysine (K)-specific methyltransferase 2A rearrangement (KMT2Ar). 27786413 2017
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with a poor clinical outcome, and is characterized by translocations of the Mixed Lineage Leukemia (MLL) gene. 27588400 2017
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy. 27841777 2017
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE Upon transplantation of MLL-AF9-transduced CB CD34<sup>+</sup> cells, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) developed in engineered scaffolds, in which a significantly higher percentage of myeloid clones was observed in the mouse compartments compared with previous models. 28456746 2017
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Acute lymphoblastic leukemia (ALL) with mixed lineage leukemia (MLL) gene rearrangements (MLL+ALL) has a dismal prognosis and is characterized by high surface CD44 expression. 28569787 2017
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE At present, all cell strains derived from acute lymphoblastic leukemia (ALL) patients with the long arm of chromosome 11 aberration are accompanied with mixed lineage leukemia (MLL) gene rearrangement. 28408741 2017
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens. 27798768 2017
Childhood Acute Lymphoblastic Leukemia
0.400 Biomarker disease BEFREE Despite the small cohort size, it could be postulated that B lineage ALL with MLL abnormalities and mature phenotype is a distinct entity that differs both from the typical Pro B ALL observed in infants and mature B-ALL with high MYC expression. 26857438 2016
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). 26914337 2016
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE To characterize the subset of ALL with normal karyotype or failed CBA, we performed fluorescence in situ hybridization (FISH) or PCR for BCR-ABL1 and MLL rearrangements as well as array comparative genomic hybridization (aCGH) in 186 adult patients. 26449660 2016
Childhood Acute Lymphoblastic Leukemia
0.400 GeneticVariation disease BEFREE Distinct from other forms of acute lymphoblastic leukemia (ALL), infant ALL with mixed lineage leukemia (MLL) gene rearrangement, the most common leukemia occurring within the first year of life, might arise without the need for cooperating genetic lesions. 24798483 2015